April 2013 Editor's Picks: Products from Axiom Analytical and I Holland - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

April 2013 Editor's Picks: Products from Axiom Analytical and I Holland

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Axiom Analytical
Shielded and self-cleaning near-infrared probes are designed for on-line analysis

Axiom added shielded and self-cleaning near-infrared (NIR) probes to its line of robust probes designed for on-line spectroscopic analysis. The FPT-850SJ NIR transmission probe includes an integral steam jacket that facilitates the elimination of condensed sample material without requiring probe removal. The FDR-825 non-contact NIR diffuse-reflectance probe uses a vortex flushing system that allows the objective optics to be effectively cleaned while in place on the process line. The on-line probes have a robust seal around the viewing window that is resistant to extreme conditions of temperature, pressure, and chemical reactivity.


I Holland
Tablet-design software aids in design of tablet parameters and performs stress analysis for tool tips

I Holland’s iTAB tablet-design software calculates tablet parameters and performs stress analysis to help users design pharmaceutical tablets. The software first calculates tablet-design parameters (e.g., volume, mass, density, and surface area) as the user modifies tablet dimensions (e.g., diameter, cup depth, and radii). The software next runs a real-time, integrated finite element analysis (FEA) simulation against the design and calculates a punch-tip maximum force. Using this analysis in the design step helps eliminate problems such as punch-tip breakage. The software produces a two-dimensional drawing and generates a design report that can be emailed to I Holland for further analysis, design work, and tooling production.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Equipment and Processing Report,
Click here